Eli Lilly and Company (LLY)
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.
Eli Lilly Has a $100 Billion Revenue Story in the Making
Eli Lilly (NYSE:LLY | LLY Price Prediction) is trading at $1,255.40, and management has guided fiscal 2026 revenue between $85 billion and $87 billion.
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
Eli Lilly has strengthened its global obesity drug market dominance, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, but rising total prescriptions and global expansion underpin continued growth prospects. Valuation has compressed to just over 30x forward earnings, reflecting market expectations for growth deceleration and ongoing pricing competition.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stock Forecast: The Market is Sleeping on Eli Lilly's Next $1 Trillion Opportunity
Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly.
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
I underestimated Eli Lilly and Company. LLY's Retatrutide showed promising efficacy in TRIUMPH-2/TRIUMPH-3 trials, and if approved by the FDA, I believe it could become the "gold standard" in the obesity market. Meanwhile, Jaypirca generated $192 million in sales for Eli Lilly in Q2, up 56.4% year-on-year, despite competitive pressure from AstraZeneca's Calquence and BeOne Medicines' Brukinsa.
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.
